Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Securities Fraud Lawsuit with the Schall Law Firm By: The Schall Law Firm via Business Wire October 08, 2024 at 18:19 PM EDT The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before December 6, 2024. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Elanco’s Zenrelia was not as safe as it portrayed to investors. The Company was unlikely to meet its own timeline for the commercial launch of Zenrelia and Credelio Quattro. The Company overstated its business prospects. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Elanco, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on businesswire.com: https://www.businesswire.com/news/home/20241008864671/en/Contacts The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 info@schallfirm.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Securities Fraud Lawsuit with the Schall Law Firm By: The Schall Law Firm via Business Wire October 08, 2024 at 18:19 PM EDT The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before December 6, 2024. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Elanco’s Zenrelia was not as safe as it portrayed to investors. The Company was unlikely to meet its own timeline for the commercial launch of Zenrelia and Credelio Quattro. The Company overstated its business prospects. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Elanco, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on businesswire.com: https://www.businesswire.com/news/home/20241008864671/en/Contacts The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 info@schallfirm.com
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before December 6, 2024. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Elanco’s Zenrelia was not as safe as it portrayed to investors. The Company was unlikely to meet its own timeline for the commercial launch of Zenrelia and Credelio Quattro. The Company overstated its business prospects. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Elanco, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on businesswire.com: https://www.businesswire.com/news/home/20241008864671/en/
